Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Medical Journal of Indonesia Jurnal Respirologi Indonesia
Wahyuni Indawati, Wahyuni
Unknown Affiliation
Health Professions Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Safety and immunogenicity of the CoV2-Bio in a healthy population aged 18 years and older in Indonesia Maria, Suzy; Olfriani, Ciho; Koesnoe, Sukamto; Sekartini, Rini; Soedjatmiko; Medise, Bernie Endyarni; Yuniar, Irene; Indawati, Wahyuni; Wirahmadi, Angga; Sari, Rini Mulia; Adi, Nuri Purwito; Retnaningdyah, Windri
Medical Journal of Indonesia Vol. 34 No. 1 (2025): March
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.13181/mji.oa.247476

Abstract

BACKGROUND According to the WHO Target Product Profiles for COVID-19 Vaccines, vaccine development should be indicated for active immunization in all populations, in conjunction with other control measures to curtail the pandemic. Several RBD-based COVID-19 vaccines are being evaluated and have shown advantages. CoV2-Bio was developed based on the wild-type SARS-CoV-2 RBD amino acid sequence, representing residues of the spike protein of the Wuhan-Hu-1 isolate. This study aimed to evaluate the safety and immunogenicity of CoV2-Bio when compared to CoronaVac. METHODS This was an observer-blinded, randomized controlled prospective study of safety and immunogenicity of the CoV2-Bio in healthy adult population. A total of 54 healthy participants were randomized to receive either 3 doses of CoV2-Bio or 2 doses of CoronaVac, and 1 dose of placebo, administered 28 days apart. Participants were followed up for safety and immunogenicity. IgG antibody titers (ELISA) and neutralization assay against Wuhan and Delta strains were evaluated at baseline, Days 28, 56, and 84. We assessed seropositive rate, seroconversion, and GMT as parameters. RESULTS Both vaccines were well tolerated and induced good antibody response. The incidence rate and intensity of local and systemic adverse events did not differ between vaccine and control groups. The vaccine group showed a larger proportion of seroconversion (4-fold increase antibody) (87.5% versus 46.2%, p = 0.001) and higher GMT (305.9 AU/ml versus 102.4 AU/ml, p<0.001) when compared to control group. CONCLUSIONS 3 doses of the CoV2-Bio are safe and immunogenic in healthy adult population. 3 doses of the CoV2-Bio COVID-19 vaccine produce a better immunogenicity profile compared to CoronaVac.
Co-Infection of Tuberculosis and COVID-19 in Children: A Case Report Jasin, Madeleine Ramdhani; Ayuningtyas, Talitha Rahma; Rafli, Achmad; Mangunatmadja, Irawan; Indawati, Wahyuni; Kaswandani, Nastiti
Jurnal Respirologi Indonesia Vol 44 No 1 (2024)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v44i1.323

Abstract

Background:Coinfection TB and COVID-19 might occur, yet few evidence has been reported. Current COVID-19 pandemic also results in disruption at TB management in the community. Case: A 5-month-old boy came with recurrent seizure, with history of persistent cough and fever for 1 month prior, also positive possible TB contact. The diagnosis was disseminated TB (miliary and meningitis), coinfected with COVID-19.Discussion: During COVID-19 pandemic, TB service in the community is disrupted resulting in delay in TB diagnosis, as observed in this patient, leading to severe manifestation. Coinfection of TB and COVID-19 can occur and may lead to more severe symptoms in either both diseases. Management of TB COVID-19 coinfected children is similar to those without COVID-19. Our patient received treatment consisting of 2 RHZE then 10 RH. Monitoring of symptoms and possible sequelae is necessary.Conclusion: Coinfection TB and COVID-19 may occur in children, and both can lead to more severe manifestation of each condition, particularly if diagnosis is delayed. Strengthening TB care in the community is essential so that there will be no delay in diagnosis, also no disruption in treatment and monitoring.Keywords COVID-19, tuberculosis, coinfection, children
Co-Authors Ayuningtyas, Talitha Rahma Bernie Endyarni Medise Irawan Mangunatmadja Irene Yuniar, Irene Jasin, Madeleine Ramdhani Maria, Suzy Nastiti Kaswandani Nuri Purwito Adi Olfriani, Ciho Rafli, Achmad Retnaningdyah, Windri Rini Mulia Sari Rini Sekartini Soedjatmiko Sukamto Koesnoe Wirahmadi, Angga